Miriam O'Sullivan
Known title: SVP, Chief HR OfficerCIK: 0002048285
Associated companies
Transaction History
| BSX | ▲ Buy | Option Exercise | 990 | $0 | 2/16/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 291 | $22K | 2/16/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,124 | $0 | 2/14/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 329 | $25K | 2/14/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 588 | $0 | 2/13/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 200 | $15K | 2/13/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 961 | $0 | 2/12/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 338 | $25K | 2/12/2026 | View on chart |
| BSX | ▼ Sell | Gift | 260 | $0 | 11/28/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,000 | $0 | 2/17/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 294 | $31K | 2/17/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 100 | $0 | 2/17/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 36 | $4K | 2/17/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 990 | $0 | 2/16/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 85 | $0 | 2/16/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 30 | $3K | 2/16/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 291 | $31K | 2/16/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,123 | $0 | 2/14/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 106 | $0 | 2/14/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 38 | $4K | 2/14/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 330 | $35K | 2/14/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 961 | $0 | 2/12/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 338 | $36K | 2/12/2025 | View on chart |
| BSX | ▲ Buy | Option Exercise | 65 | $0 | 2/12/2025 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 23 | $2K | 2/12/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.